Related Experiment Video
Updated: Jun 18, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT
Jerzy Ostrowski1, Marcin Polkowski, Agnieszka Paziewska
1Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Warsaw, Poland. jostrow@warman.com.pl
Background:
Gastrointestinal stromal tumours (GISTs) represent a heterogeneous group of tumours of mesenchymal origin characterized by gain-of-function mutations in KIT or PDGFRA of the type III receptor tyrosine kinase family. Although mutations in either receptor are thought to drive an early oncogenic event through similar pathways, two previous studies reported the mutation-specific gene expression profiles. However, their further conclusions were rather discordant. To clarify the molecular characteristics of differentially expressed genes according to GIST receptor mutations, we combined microarray-based analysis with detailed functional annotations.
Methods:
Total RNA was isolated from 29 frozen gastric GISTs and processed for hybridization on GENECHIP HG-U133 Plus 2.0 microarrays (Affymetrix). KIT and PDGFRA were analyzed by sequencing, while related mRNA levels were analyzed by quantitative RT-PCR.
Results:
Fifteen and eleven tumours possessed mutations in KIT and PDGFRA, respectively; no mutation was found in three tumours. Gene expression analysis identified no discriminative profiles associated with clinical or pathological parameters, even though expression of hundreds of genes differentiated tumour receptor mutation and expression status. Functional features of genes differentially expressed between the two groups of GISTs suggested alterations in angiogenesis and G-protein-related and calcium signalling.
Conclusion:
Our study has identified novel molecular elements likely to be involved in receptor-dependent GIST development and allowed confirmation of previously published results. These elements may be potential therapeutic targets and novel markers of KIT mutation status.
Insights
Gastrointestinal stromal tumors (GISTs) with KIT or PDGFRA mutations show distinct gene expression profiles, impacting pathways like angiogenesis and signaling. These findings offer potential therapeutic targets for GIST development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors driven by KIT or PDGFRA mutations.
- Previous studies on mutation-specific gene expression in GISTs yielded conflicting conclusions.
- Clarifying molecular differences based on receptor mutations is crucial for understanding GIST pathogenesis.
Purpose of the Study:
- To elucidate the molecular characteristics of differentially expressed genes in GISTs based on receptor mutations.
- To reconcile discordant findings from previous GIST mutation-specific gene expression studies.
- To identify novel molecular elements and potential therapeutic targets in GIST development.
Main Methods:
- Gene expression profiling using Affymetrix HG-U133 Plus 2.0 microarrays on 29 gastric GIST samples.
- Sequencing analysis of KIT and PDGFRA genes to identify mutations.
- Quantitative RT-PCR to analyze messenger RNA (mRNA) levels of related genes.
Main Results:
- Mutations were identified in KIT (15 tumors) and PDGFRA (11 tumors); 3 tumors had no mutations.
- Gene expression analysis revealed hundreds of differentially expressed genes between KIT and PDGFRA mutated GISTs.
- Functional annotation suggested significant alterations in angiogenesis, G-protein signaling, and calcium signaling pathways.
Conclusions:
- The study identified novel molecular factors involved in receptor-dependent GIST development.
- Confirmed previously reported findings regarding GIST mutation-specific gene expression.
- Highlighted potential therapeutic targets and biomarkers for KIT mutation status in GISTs.
